VASO Business Summary

VASO Corp (VASO) is a diversified medical technology company that generates revenue through three primary business segments: Professional Sales Service, Information Technology (IT), and Equipment. The Professional Sales segment, operating as VasoHealthcare, serves as the exclusive sales representative for GE HealthCare’s diagnostic imaging and ultrasound portfolio to the U.S. middle market, a partnership recently extended through December 31, 2030. The IT segment, VasoTechnology, provides managed network infrastructure, security services, and healthcare software solutions via a recurring subscription and service model. The Equipment segment, VasoMedical, focuses on the design and manufacture of proprietary medical devices, most notably its Enhanced External Counterpulsation (EECP) therapy systems for non-invasive cardiovascular treatment. Within the competitive landscape, VASO occupies a specialized niche in middle-market distribution and niche cardiac therapy, competing against larger diversified MedTech entities such as Philips, Masimo, Edwards Lifesciences, and Hologic. Leadership is anchored by President and CEO Dr. Jun Ma, who has led the company since 2008 and holds a Ph.D. in Mechanical Engineering from Columbia University. The executive team was recently restructured as of January 1, 2025, with the appointment of Jane Moen as Chief Operating Officer and the promotion of Jonathan Newton to Chief Financial Officer. The company was originally founded in 1987 as Vasomedical and is governed by a board chaired by Joshua Markowitz, with Edgar Rios serving as Vice Chairman since early 2025. Notable institutional influence is maintained by long-term stockholders including Kerns Manufacturing Corp and Living Data Technology Corp, which have historically provided strategic and financial backing to the organization.